当前位置:首页 - 行情中心 - 贝达药业(300558) - 财务分析 - 现金流量表

贝达药业

(300558)

  

流通市值:212.00亿  总市值:212.68亿
流通股本:4.19亿   总股本:4.21亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金951,635,104.643,588,039,269.522,647,137,175.411,731,866,820.84
  收到的税费返还---606,964.67
  收到其他与经营活动有关的现金62,368,694.21102,776,288.4790,716,752.8486,505,923.78
  经营活动现金流入小计1,014,003,798.853,690,815,557.992,737,853,928.251,818,979,709.29
  购买商品、接受劳务支付的现金101,230,387.32594,275,664.03402,612,013.17237,570,385.13
  支付给职工以及为职工支付的现金231,987,033.64627,573,049.47476,111,063.84329,068,745.66
  支付的各项税费109,053,453.55262,972,266.18195,901,768.51147,204,205.61
  支付其他与经营活动有关的现金308,125,235.541,294,733,670.08994,798,835.81660,158,084.68
  经营活动现金流出小计750,396,110.052,779,554,649.762,069,423,681.331,374,001,421.08
  经营活动产生的现金流量净额263,607,688.8911,260,908.23668,430,246.92444,978,288.21
二、投资活动产生的现金流量:
  收回投资收到的现金40,032,876.71---
  取得投资收益收到的现金-999,000999,000-
  处置固定资产、无形资产和其他长期资产收回的现金净额18,813.0975,286.0714,509.4214,509.42
  投资活动现金流入小计40,051,689.81,074,286.071,013,509.4214,509.42
  购建固定资产、无形资产和其他长期资产支付的现金351,944,820.43616,679,783.05481,735,187.19391,306,234.66
  投资支付的现金40,000,000312,260,000249,750,000-
  投资活动现金流出小计391,944,820.43928,939,783.05731,485,187.19391,306,234.66
  投资活动产生的现金流量净额-351,893,130.63-927,865,496.98-730,471,677.77-391,291,725.24
三、筹资活动产生的现金流量:
  吸收投资收到的现金-92,166,27892,166,27892,166,278
  取得借款收到的现金610,000,000880,000,000680,000,000580,000,000
  收到其他与筹资活动有关的现金-37,780,00037,780,000-
  筹资活动现金流入小计610,000,0001,009,946,278809,946,278672,166,278
  偿还债务支付的现金499,960,000818,340,000632,810,000532,810,000
  分配股利、利润或偿付利息支付的现金15,898,544.22150,756,175.09134,753,554.17118,423,284.56
  支付其他与筹资活动有关的现金14,326,464.9867,025,812.3439,596,154.4318,916,728.67
  筹资活动现金流出小计530,185,009.21,036,121,987.43807,159,708.6670,150,013.23
  筹资活动产生的现金流量净额79,814,990.8-26,175,709.432,786,569.42,016,264.77
四、汇率变动对现金及现金等价物的影响-504,046.511,078,742.471,901,864.44-196,210.48
五、现金及现金等价物净增加额-8,974,497.54-41,701,555.71-57,352,997.0155,506,617.26
  加:期初现金及现金等价物余额429,981,299.41471,682,855.12471,682,855.12471,682,855.12
  期末现金及现金等价物余额421,006,801.87429,981,299.41414,329,858.11527,189,472.38
补充资料:
  净利润-286,208,754.84-130,707,401.1
  资产减值准备--545,181.28--2,647,368.81
  固定资产和投资性房地产折旧-187,286,893.15-93,425,612.98
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-187,286,893.15-93,425,612.98
  无形资产摊销-360,644,562.12-176,142,112.02
  处置固定资产、无形资产和其他长期资产的损失--377,650.1--72,940.02
  固定资产报废损失-8,062.94-3,848.86
  公允价值变动损失-58,682,848.1-76,016,377.9
  财务费用-88,251,152.52-40,840,938.22
  投资损失-20,643,530.43-6,504,780.23
  递延所得税--16,274,634.29--8,304,545.62
  其中:递延所得税资产减少--3,294,921.58--3,627,974.82
    递延所得税负债增加--12,979,712.71--4,676,570.8
  存货的减少--91,593,907.31--35,869,860.82
  经营性应收项目的减少--290,901,227.75--83,045,735.68
  经营性应付项目的增加-256,977,937.5-29,486,790.15
  其他-49,417,510.2-20,254,484.88
  现金的期末余额-429,981,299.41-527,189,472.38
  减:现金的期初余额-471,682,855.12-471,682,855.12
  现金及现金等价物的净增加额--41,701,555.71-55,506,617.26
公告日期2026-04-232026-04-232025-10-282025-08-20
审计意见(境内)标准无保留意见
TOP↑